ArticleMaterials today. Bio2021
Miniaturized droplet microarray platform enables maintenance of human induced pluripotent stem cell pluripotency.
Article in Materials today. Bio, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 15 citations in OpenAlex.
- Culture of pluripotent stem cells in microscale droplets modulates differentiation and tissue patterning towards organoids on chip.Stem cell research & therapy · 2025Article
- Fe-doped MOF nanoparticles: the LIFR and BMP4 dual-signaling pathways activated regulator for in vitro expansion of mouse embryonic stem cells.Materials today. Bio · 2025Article
- Electrode Droplet Microarray (eDMA): An Impedance Platform for Label-Free Parallel Monitoring of Cellular Drug Response in Nanoliter Droplets.Advanced healthcare materials · 2025Article
- Drug-Induced Differential Gene Expression Analysis on Nanoliter Droplet Microarrays: Enabling Tool for Functional Precision Oncology.Advanced healthcare materials · 2025Article
- Design of dual peptide-conjugated hydrogels for proliferation and differentiation of human pluripotent stem cells.Materials today. Bio · 2024Article
- Droplet microarray platforms for high-throughput drug screening.Mikrochimica acta · 2023Review
- Droplet Microarray Based Screening Identifies Proteins for Maintaining Pluripotency of hiPSCs.Advanced healthcare materials · 2022Article
- "Cells-to-cDNA on Chip": Phenotypic Assessment and Gene Expression Analysis from Live Cells in Nanoliter Volumes Using Droplet Microarrays.Advanced healthcare materials · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The capacity of human induced pluripotent stem cells (hiPSCs) for indefinite self-renewal warrants their application in disease modeling, drug discovery, toxicity assays and efficacy screening. However, their poor proliferation ability, inability to adhere to surfaces without Matrigel coating and tendency to spontaneously differentiate
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.